361 Dexverapamil to overcome anthracycline-resistance in advanced breast cancer
Nicolaus Kröger(Universität Hamburg), Dieter K. Hossfeld(Universität Hamburg), Florian Schüller(RWTH Aachen University), Beat Thürlimann(University of St.Gallen), M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), H. Küpper, K. Mross, Friederike Gieseking(Universität Hamburg)
Cited by 2
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
|Journal of Clinical Oncology|2000|840
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799